82 related articles for article (PubMed ID: 18683811)
21. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
22. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases.
Cormie P; Newton RU; Spry N; Joseph D; Taaffe DR; Galvão DA
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):328-35. PubMed ID: 23917308
[TBL] [Abstract][Full Text] [Related]
24. [Current diagnosis and the multidisciplinary approach to the treatment of bone metastases in patients with prostate cancer].
Satoh T; Ishiyama H
Nihon Rinsho; 2016 Jan; 74(1):129-36. PubMed ID: 26793893
[TBL] [Abstract][Full Text] [Related]
25. Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival.
Kuroda I
Ann Nucl Med; 2014 Jan; 28(1):11-6. PubMed ID: 24127064
[TBL] [Abstract][Full Text] [Related]
26. Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases.
Walker MS; Miller PJ; Namjoshi M; Houts AC; Stepanski EJ; Schwartzberg LS
J Med Econ; 2013; 16(1):179-89. PubMed ID: 23043593
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of tumor osteopathy in cancer of the prostate].
Alcover J; Fernández-Conde M; Carrere W; Serrallach M; Carretero P
Actas Urol Esp; 1994 May; 18 Suppl():409-16. PubMed ID: 8073927
[TBL] [Abstract][Full Text] [Related]
29. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
[TBL] [Abstract][Full Text] [Related]
30. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
31. [Clinical features and prognosis in 104 colorectal cancer patients with bone metastases].
Hong RX; Lin QJ; Luo J; Dai Z; Wang WN
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):787-91. PubMed ID: 24378104
[TBL] [Abstract][Full Text] [Related]
32. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease.
Pasoglou V; Michoux N; Peeters F; Larbi A; Tombal B; Selleslagh T; Omoumi P; Vande Berg BC; Lecouvet FE
Radiology; 2015 Apr; 275(1):155-66. PubMed ID: 25513855
[TBL] [Abstract][Full Text] [Related]
33. Pros-IT CNR: an Italian prostate cancer monitoring project.
Noale M; Maggi S; Artibani W; Bassi PF; Bertoni F; Bracarda S; Conti GN; Corvò R; Gacci M; Graziotti P; Magrini SM; Maurizi Enrici R; Mirone V; Montironi R; Muto G; Pecoraro S; Porreca A; Ricardi U; Tubaro A; Zagonel V; Zattoni F; Crepaldi G;
Aging Clin Exp Res; 2017 Apr; 29(2):165-172. PubMed ID: 28236267
[TBL] [Abstract][Full Text] [Related]
34. Incidence and outcome of bone metastatic disease at University Malaya Medical Centre.
Singh VA; Haseeb A; Alkubaisi AA
Singapore Med J; 2014 Oct; 55(10):539-46. PubMed ID: 25631896
[TBL] [Abstract][Full Text] [Related]
35. [Tumors that cause bone metastases].
Ruiz-Alva SK; Cortes-Cerda R; Mora-Ríos FG; Benítez-Romero A; Isunza-Ramírez A; Mejía-Rohenes LC
Acta Ortop Mex; 2021; 35(2):201-205. PubMed ID: 34731924
[TBL] [Abstract][Full Text] [Related]
36. Reduced incidence of bone metastases in irradiated areas after external radiation therapy of prostatic carcinoma.
Jacobsson H; Näslund I
Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1297-303. PubMed ID: 2045303
[TBL] [Abstract][Full Text] [Related]
37. Gene therapy for prostate cancer bone metastasis. Gene therapy targeting bone metastasis.
Hsieh CL; Kubo H; Chung LW
Cancer Treat Res; 2004; 118():231-90. PubMed ID: 15043196
[No Abstract] [Full Text] [Related]
38. Is delayed treatment justified in carcinoma of the prostate?
Parker MC; Cook A; Riddle PR; Fryatt I; O'Sullivan J; Shearer RJ
Br J Urol; 1985 Dec; 57(6):724-8. PubMed ID: 4084734
[TBL] [Abstract][Full Text] [Related]
39. Re: Zacho et al.: Unexplained Bone Pain Is an Independent Risk Factor for Bone Metastases in Newly Diagnosed Prostate Cancer: A Prospective Study (Urology 2017;99:148-154).
Pakzad R; Safiri S
Urology; 2017 Jun; 104():243. PubMed ID: 28341577
[No Abstract] [Full Text] [Related]
40. Are we trumping bone disease in prostate cancer?
Slovin SF
Oncology (Williston Park); 2011 Dec; 25(14):1390, 1393. PubMed ID: 22329190
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
